(RTTNews) - Thursday, Amgen Inc. (AMGN) announced results from a large real-world study showing that treatment with Repatha, also known as evolocumab, reduced the risk of fatal or nonfatal heart attacks in people with atherosclerotic cardiovascular disease and prior statin use.

Amgen's Real-World Data Shows Repatha Outperforms Ezetimibe For Heart Disease 

This morning a "Potential Dividend Run Alert" went out for Amgen Inc (NASD: AMGN), at our DividendChannel.com Dividend Alerts service (a free email alerts feature).  Let's look at the situation in greater detail, shall we?

Upcoming Dividend Run For AMGN?

Amgen Inc. announced its financial results for the third quarter of 2026, reporting that total revenues increased 8% to $10.4 billion in comparison to the third quarter of 2025. GAAP earnings per share increased 19% from $5.93 to $7.08, driven by higher revenues, while non-GAAP E

Amgen Inc. Reports Third Quarter 2026 Total Revenues of $10.4 billion

Key PointsAmgen's cancer drug Imdelltra has been shown to be effective in treating advanced lung cancer when paired with AstraZeneca's Imfinzi.

Amgen Just Gave Its Shareholders Great News

Key PointsAmgen’s revenue is growing at a good clip, and it could sustain that pace despite impending patent cliffs.

Looking For Growth, Income, and Stability? This Stock Could Offer All 3 

The S&P 500 Index ($SPX ) (SPY ) is down -1.26%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.52%.  December E-mini S&P futures (ESZ26 ) are down -1.33%, and December E-mini Nasdaq futures (NQZ26...

Stocks Fall Sharply on Intel and Amazon Sell-offs and Crypto Heist

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc. News